Sarcoma

Volume 2013 (2013), Article ID 757915, 2 pages

http://dx.doi.org/10.1155/2013/757915

Erratum

Erratum to “Desmoid Fibromatosis in Pediatric Patients: Management Based on a Retrospective Analysis of 59 Patients and a Review of the Literature”

Caroline Oudot,¹ Daniel Orbach,² Véronique Minard-Colin,³ Jean Michon,² Pierre Mary,⁴ Christophe Glorion,⁵ Sylvie Helfre,⁶ Jean-Louis Habrand,⁷ and Odile Oberlin³

¹Pediatric Oncology Department, Hôpital de la Mère et de l'Enfant, 87042 Limoges, France

²Adolescent and Pediatric Oncology Department, Institut Curie, 75005 Paris, France

³Adolescent and Pediatric Oncology Department, Institut Gustave Roussy, 94800 Villejuif, France

⁴Pediatric Surgery Department, Hôpital Trousseau, 75012 Paris, France

⁵Pediatric Surgery Department, Hôpital Necker-Enfants-Malades, 75012 Paris, France

⁶Radiotherapy Department, Institut Curie, 75005 Paris, France

⁷Radiotherapy Department, Centre Hospitalier Universitaire de Caen, 14000 Caen, France

Received 16 January 2013; Accepted 31 January 2013

Copyright © 2013 Caroline Oudot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We need to update the first and third addresses as shown above. Furthermore, “zero” has been modified and replaced by “—” in Table 3.

Table 3: Efficacy of 61 chemotherapy regimens in 32 patients with measurable disease during first or any subsequent line of therapy.

CR
PR
Overall response (%)
SD
PD
Unknown response (%)

VA
6
—
1
1 (17%)
5
—
—

IVA
13
3
1
4 (30%)
9
—
—

VAC
3
—
—
—
1
1
1

VAC and tamoxifen
1
—
—
—
1
—
—

Vinblastine-MTX
14
—
7
7 (50%)
5
1
1

Vinblastine-MTX-tamoxifen
7
—
3
3 (43%)
3
—
1

Doxorubicin with other agents*
5
—
2
2 (40%)
—
3
—

Imatinib mesylate
2
—
—
—
2
—
—

Others⁺
10
—
2
2 (20%)
1
7
—

Total
61
3
16
19 (31%)
27 (44%)
12 (20%)
3 (5%)

VA: vincristine and dactinomycin; IVA: ifosfamide, vincristine and dactinomycin; VAC: vincristine, dactinomycin, and cyclophosphamide; MTX: methotrexate. : number of patients; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease. *Doxorubicin with vincristine, cisplatin, ifosfamide, cyclophosphamide, or tamoxifen. +Others: VINCAEPI (vincristine, carboplatin, and VM 26), MMT95 protocol (IVA, etoposide, epirubicin, and carboplatin), dactinomycin alone, etoposide-ifosfamide, etoposide alone, and carboplatin.